Immunome Selects Arrayjet's ArrayPlex Platform for Use in Its Discovery of Targeted Cancer Therapies
Portfolio Pulse from Benzinga Newsdesk
Immunome, Inc. (NASDAQ:IMNM), a biotech firm focusing on targeted cancer therapies, has chosen Arrayjet's ArrayPlex platform to enhance its high-throughput screening capabilities. This partnership aims to accelerate Immunome's discovery and development of cancer treatments. Arrayjet's technology, known for its inkjet liquid-handling solutions, will be accessible to Immunome and other Arrayjet customers either through CRO/CMO services or by purchasing the platform for in-house use.

March 18, 2024 | 9:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunome's partnership with Arrayjet for the ArrayPlex platform could significantly enhance its cancer therapy discovery process, potentially leading to accelerated development and commercialization of new treatments.
The partnership with Arrayjet allows Immunome to leverage advanced screening technology, which could streamline the discovery process for new cancer therapies. This technological edge may lead to faster development cycles, potentially boosting Immunome's pipeline and attracting investor interest. However, the impact on stock price will depend on further developments and market perception of this partnership's effectiveness.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90